Biosimilars, also known as follow-on-biologics are “duplicate” and licensed versions of the biologics that have lost their patent and are produced by some other company. Biosimilars have no clinically meaningful differences from the original or reference product. Moreover, regulations for biosimilar play an important
More
Amsterdam: CPhI & P-MEC India – organised by UBM – is set to welcome
[column]Everyone has been crying from the roof top that the attrition rate
Biosimilars, also known as follow-on-biologics are “duplicate” and licensed versions of the biologics that have lost their patent and are
MoreAmsterdam: CPhI & P-MEC India – organised by UBM – is set to welcome more than 50,000 attendees as the CPhI Global Pharma
More
Global pharmaceutical firms are pressuring the United States to act against India to stop more local companies producing up to
More
Inventiv Health hires a senior life sciences executive to oversee expansion of multi-faceted operations in India. Anita Tripathy Named President
More[column]Everyone has been crying from the roof top that the attrition rate is alarming, good candidates are not available, even
More
